Key | % Net Assets |
---|---|
Johnson & Johnson | 8.4% |
Pfizer Inc. | 5.4% |
Roche Holding AG | 5.1% |
GlaxoSmithKline PLC | 4.9% |
Other | 76.2% |
Name | % Net Assets |
---|---|
Johnson & Johnson | 8.4% |
Pfizer Inc. | 5.4% |
Roche Holding AG | 5.1% |
GlaxoSmithKline PLC | 4.9% |
Novartis | 4.9% |
Pfizer | 3.9% |
AstraZeneca PLC | 3.4% |
Wyeth | 3.3% |
Merck & Co., Inc | 3.2% |
Sanofi-Aventis | 3.1% |
No asset data available.
Date | 30-Oct-2024 |
---|---|
NAV | 132.90p |
Currency | GBP |
Change | -1.00p |
% | -0.75% |
YTD change | 7.50p |
YTD % | 5.98% |
Fund Inception | 01/11/2000 |
---|---|
Fund Manager | Ali Toutounchi |
TER | 0.31 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.30% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.07 |
You are here: research